NASDAQ:KURA - Kura Oncology Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $40.00
  • Forecasted Upside: 193.26 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$13.64
▲ +0.64 (4.92%)

This chart shows the closing price for KURA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kura Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KURA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KURA

Analyst Price Target is $40.00
▲ +193.26% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Kura Oncology in the last 3 months. The average price target is $40.00, with a high forecast of $80.00 and a low forecast of $21.00. The average price target represents a 193.26% upside from the last price of $13.64.

This chart shows the closing price for KURA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Kura Oncology. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/19/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/7/2022BMO Capital MarketsBoost Price Target$70.00 ➝ $80.00High
12/15/2021JMP SecuritiesReiterated RatingBuy$26.00High
11/29/2021JMP SecuritiesReiterated RatingBuy$25.00Low
11/26/2021Credit Suisse GroupLower Price TargetHold ➝ Outperform$40.00 ➝ $21.00Low
11/24/2021HC WainwrightLower Price TargetHold ➝ Buy$43.00 ➝ $32.00High
11/8/2021WedbushReiterated RatingOutperformMedium
8/6/2021Credit Suisse GroupLower Price TargetOutperform$42.00 ➝ $40.00High
8/6/2021SVB LeerinkBoost Price TargetOutperform$40.00 ➝ $41.00High
5/5/2021Credit Suisse GroupInitiated CoverageOutperform$42.00Medium
4/26/2021Credit Suisse GroupInitiated CoverageOutperform$42.00Low
2/26/2021SVB LeerinkLower Price TargetOutperform$42.00 ➝ $40.00High
2/24/2021HC WainwrightLower Price TargetBuy$45.00 ➝ $43.00High
12/7/2020WedbushBoost Price TargetOutperform$44.00 ➝ $56.00High
12/7/2020BarclaysBoost Price TargetOverweight$40.00 ➝ $47.00High
12/7/2020HC WainwrightBoost Price TargetBuy$40.00 ➝ $45.00High
12/2/2020Stifel NicolausInitiated CoverageBuy$45.00Medium
11/5/2020Piper SandlerDowngradeOverweight ➝ Neutral$25.00 ➝ $34.00Medium
10/26/2020JMP SecuritiesBoost Price Target$22.00 ➝ $33.00High
10/12/2020HC WainwrightBoost Price TargetBuy$22.00 ➝ $40.00Medium
10/8/2020CSFBBoost Price TargetOutperform$27.00 ➝ $43.00Low
10/8/2020Credit Suisse GroupBoost Price TargetOutperform$27.00 ➝ $43.00Medium
9/30/2020BarclaysBoost Price TargetPositive ➝ Overweight$32.00 ➝ $37.00Low
8/31/2020BarclaysBoost Price TargetOverweight$24.00 ➝ $32.00Medium
8/16/2020Brookline Capital ManagementReiterated RatingBuyLow
7/7/2020Credit Suisse GroupInitiated CoverageOutperform$27.00High
5/31/2020OppenheimerInitiated CoverageBuy$23.00 ➝ $27.00High
5/29/2020HC WainwrightReiterated RatingBuy$22.00High
5/19/2020Deutsche Bank AktiengesellschaftLower Price TargetBuy$28.00 ➝ $24.00Medium
5/6/2020WedbushLower Price TargetOutperform$30.00 ➝ $28.00Medium
5/5/2020OppenheimerLower Price TargetOutperform$27.00 ➝ $23.00Medium
5/5/2020HC WainwrightLower Price TargetBuy$29.00 ➝ $22.00Low
5/4/2020BarclaysInitiated CoverageOverweight$24.00Low
2/26/2020Piper SandlerLower Price Target$32.00 ➝ $30.00High
12/16/2019HC WainwrightReiterated RatingBuy$29.00Low
12/6/2019CowenReiterated RatingBuyHigh
11/6/2019CowenReiterated RatingBuyMedium
9/5/2019JMP SecuritiesReiterated RatingMarket Outperform$22.00High
9/4/2019WedbushReiterated RatingOutperform ➝ PositiveLow
8/2/2019HC WainwrightReiterated RatingBuy$29.00Low
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$28.00High
6/17/2019CowenReiterated RatingBuyMedium
6/17/2019WedbushSet Price TargetOutperform ➝ Positive$23.00 ➝ $30.00High
6/15/2019SVB LeerinkSet Price TargetBuy$27.00Low
5/24/2019CitigroupBoost Price TargetBuy$18.00 ➝ $25.00High
5/8/2019HC WainwrightSet Price TargetBuy$31.00Low
3/19/2019OppenheimerReiterated RatingBuyMedium
12/3/2018Piper Jaffray CompaniesSet Price TargetBuy$25.00High
12/3/2018HC WainwrightReiterated RatingBuy$31.00Low
11/28/2018OppenheimerSet Price TargetBuy$32.00High
11/9/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$25.00Low
11/1/2018HC WainwrightSet Price TargetBuy$31.00Medium
10/22/2018CowenReiterated RatingBuyHigh
10/22/2018HC WainwrightReiterated RatingPositive ➝ Buy$31.00High
8/7/2018HC WainwrightSet Price TargetBuy$31.00High
8/1/2018HC WainwrightInitiated CoverageBuy$31.00High
7/9/2018OppenheimerBoost Price TargetOutperform$27.00 ➝ $35.00Medium
2/16/2018CitigroupSet Price TargetBuy$28.00High
12/26/2017WedbushInitiated CoverageBuy$19.00Medium
12/20/2017WedbushInitiated CoverageOutperform$19.00High
12/11/2017OppenheimerSet Price TargetBuy$18.00High
11/16/2017OppenheimerSet Price TargetBuy$18.00N/A
11/9/2017CitigroupBoost Price TargetBuy$15.00 ➝ $19.00N/A
9/7/2017CowenInitiated CoverageOutperformMedium
8/10/2017SVB LeerinkReiterated RatingOutperform$16.00 ➝ $18.00High
8/8/2017CitigroupSet Price TargetBuy$13.00High
7/4/2017OppenheimerReiterated RatingBuy$16.00High
6/28/2017OppenheimerReiterated RatingOutperform$16.00Low
6/14/2017OppenheimerSet Price TargetBuy$16.00High
4/21/2017OppenheimerReiterated RatingOutperform$16.00Low
4/6/2017OppenheimerSet Price TargetBuy$16.00High
3/17/2017OppenheimerReiterated RatingOutperform$18.00 ➝ $16.00Low
3/6/2017OppenheimerSet Price TargetBuy$18.00N/A
2/9/2017OppenheimerReiterated RatingOutperform$16.00 ➝ $18.00N/A
(Data available from 1/18/2017 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/22/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
8/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/20/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/19/2021
  • 3 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
12/19/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/18/2022

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Kura Oncology logo
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
Read More

Today's Range

Now: $13.64
Low: $12.51
High: $13.71

50 Day Range

MA: $14.57
Low: $12.22
High: $18.41

52 Week Range

Now: $13.64
Low: $12.02
High: $36.27

Volume

512,093 shs

Average Volume

556,420 shs

Market Capitalization

$907.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Kura Oncology?

The following sell-side analysts have issued stock ratings on Kura Oncology in the last twelve months: BMO Capital Markets, Credit Suisse Group AG, HC Wainwright, JMP Securities, SVB Leerink LLC, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for KURA.

What is the current price target for Kura Oncology?

5 Wall Street analysts have set twelve-month price targets for Kura Oncology in the last year. Their average twelve-month price target is $40.00, suggesting a possible upside of 193.3%. BMO Capital Markets has the highest price target set, predicting KURA will reach $80.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $21.00 for Kura Oncology in the next year.
View the latest price targets for KURA.

What is the current consensus analyst rating for Kura Oncology?

Kura Oncology currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KURA will outperform the market and that investors should add to their positions of Kura Oncology.
View the latest ratings for KURA.

How do I contact Kura Oncology's investor relations team?

Kura Oncology's physical mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The company's listed phone number is (858) 500-8800 and its investor relations email address is [email protected] The official website for Kura Oncology is www.kuraoncology.com.